Stout Advised OpenClinica on Acquisition of BuildClinical

Stout has advised OpenClinica, a provider of eClinical software solutions and a portfolio company of Thompson Street Capital Partners (TSCP), in the acquisition of BuildClinical, the leading patient recruitment solution for academic researchers. Stout served as the exclusive financial advisor to OpenClinica in connection with the transaction.

BuildClinical, founded in 2017 and headquartered in New York City, specializes in accelerating clinical trial patient recruitment through targeted digital advertising, addressing gaps in patient awareness and access. The acquisition enables OpenClinica to offer an integrated end-to-end platform that encompasses recruitment, eligibility, consent, enrollment, and data capture, enhancing its ability to serve academic research centers, CROs, pharmaceutical sponsors, biotech companies, and medical device manufacturers.

“This acquisition represents a tremendous opportunity for OpenClinica to provide a seamless solution for clinical trial management while expanding our mission of accelerating trials and improving data quality,” said Cal Collins, Co-Founder and CEO of OpenClinica. “We are excited to work with the talented team at BuildClinical to better serve our clients and advance clinical research.”

Chad Moore, Managing Director at Stout, commented, “This acquisition highlights the importance of strategic alignment in the clinical research space, and we are proud to have played a role in bringing together two innovative organizations. Our team’s expertise and commitment to delivering exceptional outcomes were instrumental in facilitating this successful partnership, which positions OpenClinica and BuildClinical for continued growth and impact in advancing clinical trials.

BuildClinical is a health technology company that accelerates patient recruitment for clinical trials through targeted digital advertising. The company specializes in addressing patient awareness and access gaps to support academic researchers and enhance clinical trial participation.

OpenClinica provides a secure SaaS platform for automating data acquisition in clinical trials. Trusted by global leaders in life sciences, academia, and government, OpenClinica has powered more than 10,000 studies involving over 5 million patients.

Thompson Street Capital Partners is a St. Louis-based private equity firm focused on investing in founder-owned middle-market businesses in the life sciences and healthcare, software and technology, business and consumer services, and products sectors. Founded in 2000, the firm has acquired more than 150 companies and had assets under management of over $4.8 billion as of March 31, 2024. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions.

Stout’s Chad Moore and Marco Basu led the execution of the transaction.

See more information on our Investment Banking Services.